NasdaqGM:CRMDPharmaceuticals
CorMedix Buyback And Melinta Deal Recast Infection Control Growth Story
CorMedix (NasdaqGM:CRMD) has authorized a sizeable share repurchase program, signaling a new phase in its capital management approach.
The company is moving to acquire Melinta Therapeutics, which would shift CorMedix toward a broader, multi product specialty pharmaceutical profile.
Management is highlighting progress in the product pipeline for Rezzayo and DefenCath as key to this transformation.
CorMedix, currently trading at $7.43, sits at an interesting juncture after a 38.9% decline...